The Fast Money traders explain why Eli Lilly makes their "trade of the day."
Dissecting the day's major business news, with the Fast Money traders. Linda Bolton Weiser of Caris & Co. provides perspective on whether Proctor & Gamble is undervalued, and Charlie Bobrinskoy of Ariel Investments discusses his firm's heavy focus on JPMorgan.
The FMHR traders check up on how shares of JC Penney are trading since Guy Adami's trade this past May; and discuss why bond fund iShares Barclays TIPS makes today's "trade of the day."
A slower economy in China is hitting high-end retailers, like Burberry. Bryan Gildenberg, Kantar retail analyst, explains the tough situation luxury retailers are facing.
JPMorgan and Wells Fargo are getting set to report quarterly earnings on Friday before the opening bell. The FMHR shares their opinions on what investors can expect.
Cummins plunged 9 percent today on news the company lowered its Q2 and full-year guidance today, with the FMHR traders; and Applied Micro Devices & Applied Materials both slashed their estimates yesterday, with Chris Danely, JPMorgan analyst.
The Fast Money crew offers special CNBC.com-only advice on your investments.
The FMHR traders explain why they like Vodafone.
CNBC's David Faber reports on corporate America's biggest threat: cyber espionage.
Discussing unusual activity in the SPDR S&P 500 ETF, with Scott Nations of NationsShares; and Joe Weisenthal of Business Insider, discusses which events will drive this week's trading.
John Williams, UBS analyst, discusses his company's downgrade on Visa and MasterCard. "These are by no means broken companies, or broken stories, it's just right now we do not like the macro setup," says Williams.
CNBC's Melissa Lee and the Fast Money traders discuss the day's top trades and the stocks they'll be watching tomorrow.
The FMHR traders share their final trades of the hour.
CNBC's Jon Fortt reports on the details of Research In Motion; and Ed Mills, Financial Policy analyst, shares his opinions on the health-care ruling.
Google has announced its new tablet, "Nexus 7," and that it will sell for $199, reports CNBC's Jon Fortt. The Fast Money traders share their opinions.
The biotech sector is up more than 1 percent today, and discussing what investors can expect after tomorrow's health care reform ruling, with ISI's biotech and pharmaceuticals major analyst Mark Schoenebaum. "If tomorrow the whole bill is struck down, technically, earnings and revenue estimates for all of biotech and all of pharma companies are going to go up," says Schoenebaum.